$Intellia Therap(NTLA.US) surged over 13%, driven by strong Phase 3 data for hereditary angioedema, which is expected to facilitate a rolling BLA submission. The potential U.S. launch is targeting the first half of 2027. Q1 revenue of $15 million also exceeded expectations, with net losses narrowing year-over-year. Cathie Wood's ARK bought 214,000 shares in a single day.
What the gene editing sector currently lacks is the "delivery of clinical milestones." This time, the combination of strong Phase 3 data, regulatory progress, and institutional buying provides fundamental support for the sharp rise. The next focus will be on the review timeline for the BLA.
The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
